Quarterly report pursuant to Section 13 or 15(d)

Segments - Operations and Assets Information (Details)

v3.20.1
Segments - Operations and Assets Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Segment Reporting Information [Line Items]      
Total revenues $ 211,466 $ 222,451  
Operating loss (40,762) (75,318)  
Depreciation and amortization 22,052 23,816  
Net income (loss) from investment in investees (134) (1,854)  
Assets 2,232,542   $ 2,309,272
Goodwill 669,582   671,940
United States      
Segment Reporting Information [Line Items]      
Total revenues 180,872 184,894  
Ireland      
Segment Reporting Information [Line Items]      
Total revenues 11,901 20,534  
Chile      
Segment Reporting Information [Line Items]      
Total revenues 10,850 7,865  
Spain      
Segment Reporting Information [Line Items]      
Total revenues 4,156 4,418  
Israel      
Segment Reporting Information [Line Items]      
Total revenues 1,707 3,116  
Mexico      
Segment Reporting Information [Line Items]      
Total revenues 1,841 1,531  
Other      
Segment Reporting Information [Line Items]      
Total revenues 139 93  
Corporate      
Segment Reporting Information [Line Items]      
Operating loss (8,503) (12,272)  
Depreciation and amortization 60 19  
Net income (loss) from investment in investees 0 0  
Assets 48,232   99,521
Goodwill 0   0
Pharmaceutical | Operating Segments      
Segment Reporting Information [Line Items]      
Operating loss (14,126) (29,477)  
Depreciation and amortization 7,121 7,526  
Net income (loss) from investment in investees (134) (1,854)  
Assets 1,157,430   1,174,639
Goodwill 234,773   237,131
Diagnostics | Operating Segments      
Segment Reporting Information [Line Items]      
Operating loss (18,133) (33,569)  
Depreciation and amortization 14,871 16,271  
Net income (loss) from investment in investees 0 0  
Assets 1,026,880   1,035,112
Goodwill 434,809   $ 434,809
Services      
Segment Reporting Information [Line Items]      
Total revenues 170,839 178,891  
Services | Corporate      
Segment Reporting Information [Line Items]      
Total revenues 0 0  
Services | Pharmaceutical | Operating Segments      
Segment Reporting Information [Line Items]      
Total revenues 0 0  
Services | Diagnostics | Operating Segments      
Segment Reporting Information [Line Items]      
Total revenues 170,839 178,891  
Products      
Segment Reporting Information [Line Items]      
Total revenues 31,074 25,301  
Products | Pharmaceutical | Operating Segments      
Segment Reporting Information [Line Items]      
Total revenues 31,074 25,301  
Transfer of intellectual property and other      
Segment Reporting Information [Line Items]      
Total revenues 9,553 18,259  
Transfer of intellectual property and other | Corporate      
Segment Reporting Information [Line Items]      
Total revenues 0 0  
Transfer of intellectual property and other | Pharmaceutical | Operating Segments      
Segment Reporting Information [Line Items]      
Total revenues 9,553 18,259  
Transfer of intellectual property and other | Diagnostics | Operating Segments      
Segment Reporting Information [Line Items]      
Total revenues $ 0 $ 0